Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model

International Journal of Cancer

Volumn 138, Issue 1, 2016, Pages 187-194

  Mathios, Dimitrios ^a   Park, Chul Kee ^a,b   Marcus, Warren D ^c   Alter, Sarah ^c   Rhode, Peter R ^c   Jeng, Emily K ^c   Wong, Hing C ^c   Pardoll, Drew M ^a   Lim, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Seoul National University College of Medicine   (South Korea)

^c ALTOR BIOSCIENCE CORPORATION   (United States)

Author keywords

ALT 803; anti PD 1; glioblastoma; IL 15 superagonist

Indexed keywords

ALT 803; ANTIBODY; ANTINEOPLASTIC AGENT; GAMMA INTERFERON; PD 1 ANTIBODY; UNCLASSIFIED DRUG; ALT-803; INTERLEUKIN 15; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; STEREOTACTIC RADIOSURGERY; SURVIVAL TIME; TUMOR IMMUNITY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MORTALITY; PATHOLOGY; RADIOSURGERY; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERLEUKIN-15; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEINS; RADIOSURGERY; T-LYMPHOCYTE SUBSETS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944280347     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29686     Document Type: Article

References (29)

1. Ostrom QT, Gittleman, H, Liao P, et al., CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-Oncology 2014; 16 Suppl 4: Iv1-63.
2. Stupp R, Mason, WP, van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine 2005; 352: 987-96.
3. Chae M, Peterson TE, Balgeman A, et al., Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Neuro oncology, 2015; 17: 978-91.
4. Authier A, Farrand KJ, Broadley KW, et al., Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells. International Journal of Cancer, 2015; 136: 2566-78.
5. Bloch O, Crane CA, Kaur R, et al., Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2013; 19: 3165-75.
6. Brooks WH, Netsky MG, Normansell DE, et al., Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. The Journal of Experimental Medicine 1972; 136: 1631-47.
7. Grossman SA, Ye, X, Lesser G, et al., Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011; 17: 5473-80.
8. Prins RM, Soto, H, Konkankit V, et al., Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011; 17: 1603-15.
9. Pardoll DM., The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer 2012; 12: 252-64.
10. Pardoll DM., Immunology beats cancer: A blueprint for successful translation. Nature Immunology 2012; 13: 1129-32.
11. Zeng J, See, AP, Phallen J, et al., Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. International Journal of Radiation Oncology, Biology, Physics 2013; 86: 343-9.
12. Belcaid Z, Phallen, JA, Zeng J, et al., Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PloS One 2014; 9: E101764
13. Sharabi AB, Nirschl CJ, Kochel CM, et al., Stereotactic radiation therapy augments antigen-specific PD-1 mediated anti-tumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015; 3: 345-55.
14. Nicholas S, Mathios D, Ruzevick J, et al., Current trends in glioblastoma multiforme treatment: Radiation therapy and immune checkpoint inhibitors. Brain Tumor Research and Treatment 2013; 1: 2-8.
15. Waldmann TA., The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nature Reviews Immunology 2006; 6: 595-601.
16. Liu K, Catalfamo M, Li Y, et al., IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells. Proc Natl Acad Sci U S A 2002; 99: 6192-7.
17. Waldmann TA, Lugli, E, Roederer M, et al., Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011; 117: 4787-95.
18. Mier JW, Brandon EP, Libby P, et al., Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy. Journal of Immunology 1989; 143: 2407-14.
19. Garofalo S, D'Alessandro, G, Chece G, et al., Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice. Nat Commun 2015; 6: 6623
20. Wong HC, Jeng EK, Rhode PR., The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8 T cells into innate-like effector cells with antitumor activity. Oncoimmunology 2013; 2: E26442
21. Epardaud M, Elpek, KG, Rubinstein MP, et al., Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Research 2008; 68: 2972-83.
22. Xu W, Jones, M, Liu B, et al., Efficacy and mechanism-of-action of a novel superagonist interleukin-15: Interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Research 2013; 73: 3075-86.
23. Gomes-Giacoia E, Miyake, M, Goodison S, et al., Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PloS One 2014; 9: E96705
24. Hirano F, Kaneko, K, Tamura H, et al., Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Research 2005; 65: 1089-96.
25. Segal BM, Glass DD, Shevach EM., Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection. Journal of Immunology 2002; 168: 1-4.
26. Vetter M, Hofer MJ, Roth E, et al., Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma. J Neuropathol Exp Neurol 2009; 68: 525-34.
27. Smith KE, Fritzell, S, Badn W, et al., Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells. International Journal of Cancer Journal International Du Cancer 2009; 124: 630-7.
28. Dillman RO, Duma, CM, Ellis RA, et al., Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother 2009; 32: 914
29. Jacobs SK, Wilson, DJ, Melin G, et al., Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: Clinical and experimental studies. Neurol Res 1986; 8: 81-7.